BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 29568923)

  • 1. ATM‑JAK‑PD‑L1 signaling pathway inhibition decreases EMT and metastasis of androgen‑independent prostate cancer.
    Zhang L; Xu LJ; Zhu J; Li J; Xue BX; Gao J; Sun CY; Zang YC; Zhou YB; Yang DR; Shan YX
    Mol Med Rep; 2018 May; 17(5):7045-7054. PubMed ID: 29568923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined inhibition of JAK1,2/Stat3‑PD‑L1 signaling pathway suppresses the immune escape of castration‑resistant prostate cancer to NK cells in hypoxia.
    Xu LJ; Ma Q; Zhu J; Li J; Xue BX; Gao J; Sun CY; Zang YC; Zhou YB; Yang DR; Shan YX
    Mol Med Rep; 2018 Jun; 17(6):8111-8120. PubMed ID: 29693186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Crosstalk Between Castration-Resistant Prostate Cancer Cells, M2 Macrophages, and NK Cells: Role of the ATM-PI3K/AKT-PD-L1 Pathway.
    Jin H; Zhu J; Xuan R; Zhou Y; Xue B; Yang D; Gao J; Zang Y; Xu L
    Immunol Invest; 2023 Nov; 52(8):941-965. PubMed ID: 37732622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of IL-6-JAK/Stat3 signaling in castration-resistant prostate cancer cells enhances the NK cell-mediated cytotoxicity via alteration of PD-L1/NKG2D ligand levels.
    Xu L; Chen X; Shen M; Yang DR; Fang L; Weng G; Tsai Y; Keng PC; Chen Y; Lee SO
    Mol Oncol; 2018 Mar; 12(3):269-286. PubMed ID: 28865178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MET inhibition enhances PARP inhibitor efficacy in castration-resistant prostate cancer by suppressing the ATM/ATR and PI3K/AKT pathways.
    Zhou S; Dai Z; Wang L; Gao X; Yang L; Wang Z; Wang Q; Liu Z
    J Cell Mol Med; 2021 Dec; 25(24):11157-11169. PubMed ID: 34761497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N-Myc promotes therapeutic resistance development of neuroendocrine prostate cancer by differentially regulating miR-421/ATM pathway.
    Yin Y; Xu L; Chang Y; Zeng T; Chen X; Wang A; Groth J; Foo WC; Liang C; Hu H; Huang J
    Mol Cancer; 2019 Jan; 18(1):11. PubMed ID: 30657058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adipocytes affect castration-resistant prostate cancer cells to develop the resistance to cytotoxic action of NK cells with alterations of PD-L1/NKG2D ligand levels in tumor cells.
    Xu L; Shen M; Chen X; Zhu R; Yang DR; Tsai Y; Keng PC; Chen Y; Lee SO
    Prostate; 2018 Apr; 78(5):353-364. PubMed ID: 29330929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tpl2 induces castration resistant prostate cancer progression and metastasis.
    Lee HW; Cho HJ; Lee SJ; Song HJ; Cho HJ; Park MC; Seol HJ; Lee JI; Kim S; Lee HM; Choi HY; Nam DH; Joo KM
    Int J Cancer; 2015 May; 136(9):2065-77. PubMed ID: 25274482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of ATM reverses EMT and decreases metastatic potential of cisplatin-resistant lung cancer cells through JAK/STAT3/PD-L1 pathway.
    Shen M; Xu Z; Xu W; Jiang K; Zhang F; Ding Q; Xu Z; Chen Y
    J Exp Clin Cancer Res; 2019 Apr; 38(1):149. PubMed ID: 30961670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin-6/signal transducer and activator of transcription 3 promotes prostate cancer resistance to androgen deprivation therapy via regulating pituitary tumor transforming gene 1 expression.
    Huang S; Liu Q; Liao Q; Wu Q; Sun B; Yang Z; Hu X; Tan M; Li L
    Cancer Sci; 2018 Mar; 109(3):678-687. PubMed ID: 29288516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of LSD1 by Pargyline inhibited process of EMT and delayed progression of prostate cancer in vivo.
    Wang M; Liu X; Guo J; Weng X; Jiang G; Wang Z; He L
    Biochem Biophys Res Commun; 2015 Nov; 467(2):310-5. PubMed ID: 26435505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Banxia xiexin decoction affects drug sensitivity in gastric cancer cells by regulating MGMT expression via IL‑6/JAK/STAT3‑mediated PD‑L1 activity.
    Feng X; Xue F; He G; Ni Q; Huang S
    Int J Mol Med; 2021 Aug; 48(2):. PubMed ID: 34278452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer.
    Hao J; Ci X; Xue H; Wu R; Dong X; Choi SYC; He H; Wang Y; Zhang F; Qu S; Zhang F; Haegert AM; Gout PW; Zoubeidi A; Collins C; Gleave ME; Lin D; Wang Y
    Eur Urol; 2018 Jun; 73(6):949-960. PubMed ID: 29544736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HDAC inhibition impedes epithelial-mesenchymal plasticity and suppresses metastatic, castration-resistant prostate cancer.
    Ruscetti M; Dadashian EL; Guo W; Quach B; Mulholland DJ; Park JW; Tran LM; Kobayashi N; Bianchi-Frias D; Xing Y; Nelson PS; Wu H
    Oncogene; 2016 Jul; 35(29):3781-95. PubMed ID: 26640144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PRKAR2B promotes prostate cancer metastasis by activating Wnt/β-catenin and inducing epithelial-mesenchymal transition.
    Sha J; Han Q; Chi C; Zhu Y; Pan J; Dong B; Huang Y; Xia W; Xue W
    J Cell Biochem; 2018 Sep; 119(9):7319-7327. PubMed ID: 29761841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epithelial mesenchymal-like transition occurs in a subset of cells in castration resistant prostate cancer bone metastases.
    Haider M; Zhang X; Coleman I; Ericson N; True LD; Lam HM; Brown LG; Ketchanji M; Nghiem B; Lakely B; Coleman R; Montgomery B; Lange PH; Roudier M; Higano CS; Bielas JH; Nelson PS; Vessella RL; Morrissey C
    Clin Exp Metastasis; 2016 Mar; 33(3):239-48. PubMed ID: 26667932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ATM deficiency promotes progression of CRPC by enhancing Warburg effect.
    Xu L; Ma E; Zeng T; Zhao R; Tao Y; Chen X; Groth J; Liang C; Hu H; Huang J
    Endocr Relat Cancer; 2019 Jan; 26(1):59-71. PubMed ID: 30400006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SPP1 Promotes Enzalutamide Resistance and Epithelial-Mesenchymal-Transition Activation in Castration-Resistant Prostate Cancer via PI3K/AKT and ERK1/2 Pathways.
    Pang X; Zhang J; He X; Gu Y; Qian BZ; Xie R; Yu W; Zhang X; Li T; Shi X; Zhou Y; Cui Y
    Oxid Med Cell Longev; 2021; 2021():5806602. PubMed ID: 34721759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of LOXL2 Enhances the Radiosensitivity of Castration-Resistant Prostate Cancer Cells Associated with the Reversal of the EMT Process.
    Xie P; Yu H; Wang F; Yan F; He X
    Biomed Res Int; 2019; 2019():4012590. PubMed ID: 30809541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppression of TRPM7 Inhibited Hypoxia-Induced Migration and Invasion of Androgen-Independent Prostate Cancer Cells by Enhancing RACK1-Mediated Degradation of HIF-1
    Yang F; Cai J; Zhan H; Situ J; Li W; Mao Y; Luo Y
    Oxid Med Cell Longev; 2020; 2020():6724810. PubMed ID: 32215176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.